A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia

Journal of Psychopharmacology

Volumn 21, Issue 4, 2007, Pages 421-427

  Lee, Bong Ju ^a   Lee, Jung Goo ^b   Kim, Young Hoon ^a,c  

^a Inje University College of Medicine   (South Korea)

^b Dong Suh Mental Hospital   (South Korea)

^c Inje University   (South Korea)

Author keywords

Cognition; Donepezil; Schizophrenia

Indexed keywords

DONEPEZIL; HALOPERIDOL; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MENTAL PATIENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RECALL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VERBAL MEMORY; VISUAL MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; CHRONIC DISEASE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HALOPERIDOL; HUMANS; INDANS; PIPERIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34447546649     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106070996     Document Type: Article

References (31)

1. Blyler C.R., Gold J.M. (2000) Cognitive effects of typical antipsychotic treatment: another look. In Sharma T, Harvey P (eds). Cognition in Schizophrenia. New York: Oxford University Press, pp. 241 - 265
2. Brandt J. (1991) The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. The Clinical Neuropsychologist 5: 125 - 142
3. Brocks A., Little J.T., Martin A., Minichiello M.D., Dubbert B., Mack C., Tune L., Murphy D.L., Sunderland T. (1998) The influence of ondasetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Biol Psychiatry 43: 408 - 416
4. Buchanan R.W., Summerfelt A., Tek C., Gold J. (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59 (1). 29 - 33
5. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48: 381 - 388
6. Crowe S.F. (1998) Decrease in performance on the verbal fluency test as a function of time: evaluation in a young healthy sample. J Clin Exp Neuropsychol 20 (3). 391 - 401
7. Cuesta M.J., Peralta V., Zarzuela A. (1998) Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res 33 (3). 141 - 150
8. Davis K.L., Kahn R.S., Ko G., Davidson M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148 (11). 1474 - 1486
9. Freedman R., Hall M., Adler L.E., Leonard S. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22 - 33
10. Friedman J.I., Temporini H., Davis K.L. (1999) Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45 (1). 1 - 16
11. Friedman J.I., Adler D.N., Howanitz E., Harvey P.D., Brenner G., Temporini H., White L., Parrella M., Davis K.L. (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51 (5). 349 - 357
12. Freudenreich O., Herz L., Deckersbach T., Evins A.E., Henderson D.C., Cather C., Goff D.C. (2005) Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology. Published online: 19 March
13. Furey M.L., Pietrini P., Haxby J.V. (2000) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 290: 2315 - 2319
14. Goldberg T.E., Gold J.M. (1995) Neurocognitive functioning in patients with schizophrenia: an overview. In Bloom F E, Kupfer D J (eds). Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press ; pp. 1245 - 1257
15. Green M.F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 53 (3). 321 - 330
16. Kang Y.W., Na D.L., Han S.H. (1997) A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 15: 300 - 308
17. Karson C.N., Mrak R.E., Husain M.M., Griffin W.S. (1996) Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 29 (23). 181 - 191
18. Keefe R.S., Silva S.G., Perkins D.O., Lieberman, J.A. (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25 (2). 201 - 222
19. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. (1996) Nicotinic receptor function in schizophrenia. Schizophr Bull 22: 431 - 445
20. Mitrushina M., Satz P. (1995) Repeated testing of normal elderly with the Boston Naming Test. Aging (Milano) 7 (2). 123 - 127
21. Moering R.G., Schinka J.A., Mortimer J.A., Graves A.B. (2004) Normative data for elderly African Americans for the Stroop Color and Word Test. Arch Clin Neuropsychol 19 (1). 61 - 71
22. Park J.H., Kwon Y.C. (1990) Modification of the mini-mental state examination for use in the elderly in a non-western society: Part I. Development of Korean version of Mini-Mental State Examination. Int J Geriatr Psychiatry 5: 381 - 387
23. Park J.H., Park Y.N., Ko H.J. (1991) Modification of the Mini-Mental State Examination for use in the elderly in a non-western society: Part II. Cutoff points and their diagnostic validities. Int J Geriatr Psychiatry 6: 875 - 882
24. Poulton R.G., Moffitt T.E. (1995) The Rey-Osterreith Complex Figure Test: norms for young adolescents and an examination of validity. Arch Clin Neuropsychol 10 (1). 47 - 56
25. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., Breier A., Tollefson G.D. (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249 - 258
26. Reitan R.M. (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills 8: 271 - 276
27. Risch S.C., McGurk S., Horner M.D., Nahas Z., Owens S.D., Molloy M., Gilliard C., Christie S., Markowitz J.S., DeVane C.L., Mintzer J., George M.S. (2001) A double-blind placebo-controlled case study of the use of donepezil to improve cognition in aschizoaffective disorder patient: functional MRI correlates. Neurocase 7 (2). 105 - 110
28. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. (1998) Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158: 1021 - 1031
29. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Kurachi M., Uehara T., Sumiyoshi C., Meltzer H.Y. (2001) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49 (10). 861 - 868
30. Tugal O., Yazici K M., Anil Yagcioglu A E., Gogus A. (2004) A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 7 (2). 117 - 123
31. Vitiello B., Martin A., Hill J., Mack C., Molchan S., Martinez R., Murphy D.L., Sunderland T. (1997) Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropharmacology 16: 15 - 24